Rationale and design of the ETN-STEP (Early administration of Tirofiban in mid to high ris
Rationale and design of the ETN-STEP (Early administration of Tirofiban in mid to high risk patients with non-ST elevation acute coronary syndrome referred for percutaneous coronary intervention) project: A multi-center, randomized,
controlled clinic tria
Jian-Ping Li;Qun Liu;Yong Huo
【期刊名称】《老年心脏病学杂志(英文版)》 【年(卷),期】2012(009)004
【摘要】As a member of Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors, Tirofiban had been shown to improve myocardial reperfusion and clinical outcomes in patients undergoing percutaneous coronary intervention (PCI), but the optimal timing of administration of Tirofiban remains unclear. In order to compare the effects of upstream versus downstream administration of Tirofiban in Chinese patients with mid to high risk,non-ST elevation acute coronary syndrome (ACS) referred for PCI, a multi-center, randomized, controlled, prospective study will be conducted. A total of 500 mid to high risk, non-ST-segment elevation myocardial infarction (NSTEMI) ACS patients will be recruited for this study. Patients will be randomized to Tirofiban upstream administration group (initiated 12 h before PCI) and Tirofiban downstream administration group (initiated at cath-lab after angiography).
Rationale and design of the ETN-STEP (Early administration of Tirofiban in mid to high ris
![](/skin/haowen/images/icon_star.png)
![](/skin/haowen/images/icon_star.png)
![](/skin/haowen/images/icon_star.png)
![](/skin/haowen/images/icon_star.png)